Stock Detail
BIOVAIL CORPORATION
BVF @ Yahoo Finance | BVF Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $26.35 | $26.35 | $0.00 | 0.00% | 0.00 | $26.35 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $0.00 | $0.00 | 0 | 0 | 0 | 0.00 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 43.92 | 35.14 | 17.57 | 8.79 | -8.78 |
Stock Profile
Biovail Corporation engages in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products utilizing oral drug-delivery technologies primarily in North America. Its primary focus is on various therapeutic areas, including cardiovascular disease, central nervous system disorders, and pain management. The company's portfolio of oral drug-delivery technologies include controlled release, graded release, enhanced absorption, rapid absorption, taste masking, and oral disintegration. Biovail's products are commercialized in various countries through licensing agreements with strategic marketing partners. In addition, the company promotes and/or co-promotes products on behalf of third parties; provides research, development, and clinical contract research services to third parties; and sells its controlled release products through third parties. Biovail was founded in 1983 and is headquartered in Mississauga, Canada.